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Abstract The influence of fosfomycin on methicillin-
resistant Staphylococcus pseudintermedius (MRSP) as the
target cell was studied by atomic force microscopy (AFM).
Nanoscale images of the effects of the antibiotic fosfo-
mycin on this gram-positive bacterium’s cell were obtained
in situ without fixing agents. Our study has demonstrated
substantial morphological and topographical differences
between the control and fosfomycin-treated MRSP cells.
The AFM investigations further revealed the rough surface
morphology and a 30 % shrinkage in size of the fosfo-
mycin-treated cell and the leakage of cytoplasmic com-
ponents from the cell. The damage of cell membrane
integrity and the cell surface degradation as observed
elaborates the antibacterial activity of fosfomycin. The
AFM image analysis also reveals that the fosfomycin
inhibits cell division, and prevents the adhesion on the
surface discouraging the biofilm attachment. The micro-
titre plate assay results conform to the atomic force
microscopy image analysis. This is the first visual dem-
onstration of the effect of fosfomycin on MRSP cells.
Keywords Staphylococcus pseudintermedius  Atomic
force microscopy  Fosfomycin  Cell wall antimicrobial 
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Introduction
Staphylococcus pseudintermedius is a major cause of
morbidity and has been increasingly found in the skins and
ears of companion animals leading to economic loss in
animal health. Methicillin-resistant Staphylococcus pseud-
intermedius (MRSPs) are the frequent cause of pyoderma,
urinary tract infections and otitis (Borjesson et al. 2012;
Kadlec et al. 2010; Rubin et al. 2011). As an opportunistic
pathogen, these gram-positive Staphylococcus pseudinter-
medius cocci can occasionally cause infections in humans
(Chuang et al. 2010; Hoovels et al. 2006). Due to the
emergence and widespread dissemination of MRSP, it
becomes an expensive and a serious challenge to control or
eradicate these pathogenic biofilms using antibiotics.
MRSP ST71 has been reported (Stegmann et al. 2010) to
cause human infection from companion animals demon-
strating the therapeutic challenge and its zoonotic potential.
MRSP isolates are resistant to several clinically useful
antibiotics including b-lactam agent such as clarithromycin
(DiCicco et al. 2012). Fosfomycin is a wide spectrum
antibiotic used for treating urinary tract and genital tract
infections caused by both gram-positive and gram-negative
bacterial strains (Falagas et al. 2010). Fosfomycin exert
antimicrobial activity by inhibiting UDP-N-acetylglucosa-
mine enolpyruvyl transferase enzyme (Eschenburg et al.
2005) that catalysis the first step in bacterial cell-wall
synthesis within the cell. Fosfomycin has the ability to
penetrate into the fluid of the interstitial space of soft tis-
sues (Frossard et al. 2000) to reach levels sufficient to
substantially inhibit the growth of relevant bacteria at the
target site. The pharmacokinetic and pharmacodynamic
properties of fosfomycin facilitate design of drug doses
with clinically relevant concentrations for sites such as
lungs, bone, soft tissue, and serum and heart valves
(Roussos et al. 2009). So far, there have been no reports of
fosfomycin’s cross-resistance to other antibiotics. Further,
the lower molecular weight of fosfomycin (138.059 g/mol)
makes it an attractive agent for designing lower microbial
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inhibition concentration drugs. Hence, fosfomycin could be
a promising alternate candidate for the treatment of
infections caused by MRSP biofilms.
To further extend the understanding of clinical relevance
in recommending fosfomycin for treating MRSP biofilms, it
is necessary to understand the antimicrobial activity of fos-
fomycin at the nanoscale level. Atomic Force Microscopy
(AFM) imaging technique overcomes the drawbacks of
Scanning Electron Microscopy (SEM) such as the need for
conductive coating on biofilm samples for SEM imaging,
extensive sample preparation techniques, and the vacuum
requirement during imaging. Confocal Laser Scanning
Imaging (CLSM) can image the bacterial cells at their
physiological conditions, but offers only at macroscopic
level. Hence, AFM proves to be superior compared to both
SEM and CLSM in imaging the biofilms at the nanoscale
level. AFM experiments has been carried out to investigate
the effects of antimicrobial and antibiotic properties of
chitosans (Eaton et al. 2008), kyotorphin peptide (Ribeiro
et al. 2012), carvacrol (Storia et al. 2011) on Staphylococcal
aureus biofilms. The nanoscale visualization and charac-
terization of Staphylococcus aureus cells (Ribeiro et al.
2012) demonstrated that kyotorphin perturbed the bacterial
cell-wall membrane by blebbing, lysis and disruption. The
molecular mechanism of nanoconjugated vancomycin
(Chakraborty et al. 2012) towards antimicrobial therapeutic
approaches in treating Staphylococcus aureus at the nano-
scale proved that AFM is a potential tool in understanding the
types of antimicrobial induced bacterial cell-wall damage.
The effects of various antibiotic candidates on MRSA have
been studied in detail; however to-date there has been no
nanoscale investigation of antimicrobial agents on MRSPs.
Both MRSPs and MRSAs are gram-positive cocci, but
MRSPs are distinctly different than MRSAs. The spread of
mecA gene in S. aureus and S. pseudintermedius occur via
independent routes, and hence MRSAs are distinctly different
than the MRSP from an evolutionary point of view (Sasaki
et al. 2007). Moreover, the resistance pattern to antibiotics is
different between MRSA and MRSP due to their different
biological behaviors. Here, we evaluate the evidence on fos-
fomycin as a treatment option against MRSP biofilms using
atomic force microscopy. The objective of this work is to
elucidate the antimicrobial activity of fosfomycin on MRSP
using AFM imaging techniques. This is the first report on the
visual investigation of the effect of fosfomycin on MRSPs.
Methods
Chemicals and materials
MRSP A12 strains collected from the Centre for Public
Health and Zoonotic Diseases of the Ontario Veterinary
College was used to investigate the effect of fosfomycin.
Fosfomycin (FOS) was acquired from Sigma Chemical Co
(St. Louis, MO, USA).
Preparation of bacterial samples for morphology studies
MRSP A12 isolate was sub-cultured for 24 h at 35 C in
Columbia Agar with 5 % sheep blood plates. Upon 24 h,
the isolate was added to nutrient-rich tryptic soy broth
supplemented with 1 % glucose (TSB-G) in 10 ml tubes
and was grown to late mid-log phase at 1 9 106 CFU/ml.
The cells in 1.0 ml culture were centrifuged in a Scilogex
Model D3024 microfuge at 3,500 rpm for 3 min at room
temperature, and washed 3 times with 1 volume of sterile
analytical-grade water. The pellet was again suspended in
deionized distilled water and the concentration of the
bacteria was measured by a spectrophotometer at 420 nm.
Freshly cleaved mica sheets were added to petri-dishes
containing the bacterial cell culture suspension with and
without 8 lg/ml FOS and incubated for 24 h at 35 C. At
4, 8, 12 and 24 h of incubation, the mica sheets were gently
removed using fine tip tweezers, washed in free-flowing
nanopure water to remove the freely attached cells and
dried at room temperature for 3 h before imaging. AFM
imaging was carried out for both the control samples and
the bacterial culture treated with fosfomycin. Analysis was
done with duplicate cultures for each time point.
AFM imaging
MRSP A12 cells were imaged in air with a tapping mode
atomic force microscope (Dimension Icon SPM, Bruker)
before and after being treated with antibiotics. AFM height,
amplitude and phase images were obtained in AC mode on
the air-dried mica substrates. A triangular Si cantilever tip
(Bruker AFM Probes, Camarilla, CA, USA) with a spring
constant of 0.35 N/m and a resonance frequency of 18 kHz
was used. A scan speed of 0.7–1.5 Hz was set and resulted
in a final resolution of 512 by 512 pixels.
Results and discussion
The cocci or the spheroid cell shape morphology is evident
from the AFM images (Fig. 1) of the untreated cells. AFM
image analysis revealed that the surface ultrastructure of
both MRSP ST72 strains and the cells treated with fosfo-
mycin (Fig. 2) are completely different. The healthy MRSP
cells are distinguishable from the fosfomycin exposed
cells. The untreated MRSP cells have a relatively smooth
surface without pores or any ruptures in comparison with
the grooves on the fosfomycin-treated cells. Grooves or
depressions or holes distributed on every cell surface
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demonstrate the shape alterations induced by fosfomycin.
The surface of fosfomycin-treated MRSP A12 biofilms
(Fig. 2b) has densely packed surface subunits made of
small aggregates of surface molecules.
Significant differences in cellular dimensions between
control and the fosfomycin-treated MRSP cells (Fig. 3a,
b) are observed from the AFM images. The statistical
results of the average diameter of the cocci-shaped gram-
positive MRSP A12 untreated cells and the fosfomycin-
treated cells obtained from the AFM height images are
1,008 ± 123 and 780 ± 100 lm respectively. The phar-
macological antimicrobial mechanism of fosfomycin is
based on the cell-wall biosynthesis inhibition process.
Briefly, fosfomycin inactivates the MurA proteins which
are present at the transition between cytoplasmic synthesis
of the uridine diphosphate (UDP)-linked precursor by
mimicking phosphoenolpyruvate and by irreversibly
modifying the critical active-site nucleophile Cys115
through a covalent linkage (Lovering et al. 2012; Kahan
et al. 1974). The structure of fosfomycin is shown in
Fig. 4. A therapeutic dosage of 8 lg/ml concentration of
fosfomycin was chosen to test the efficacy against MRSP
biofilms based on the Clinical and Laboratory Standards
Institute guidelines (CLSI, PA, USA) and this dosage can
be attained in humans by oral or parenteral administra-
tion. Hence the influence of different concentrations of
fosfomycin on MRSP A12 cells was not explored in this
study.
The surface roughness of the cells was calculated as a
quantitative assessment of the surface texture with the
average of the vertical deviations from the nominal surface
over a specified area (Dong et al. 2011). The roughness
differences on the ultra-structural surface of fosfomycin-
treated cells have accounted for the change in cell shape
Fig. 1 Topographical images
of MRSP A12 cells before
(a) and after being treated with
fosfomycin (b)
Fig. 2 AFM images of MRSP A12 control (a) and fosfomycin-treated (b) cells. Shown are fixed whole cells (a, b) and corresponding surface
ultrastructure (c, d). Bars 100 nm
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greatly. The increase in the numerical surface roughness
suggests the efficiency of fosfomycin in interacting with
the cellular membrane.
The action effects of fosfomycin on the MRSP cells over
various periods of treatment are shown in Fig. 3. Time-
course study investigating the effect of fosfomycin on the
Fig. 3 Time dependence of fosfomycin effects on MRSP imaged by
AFM. Three-dimensional orthogonal projection images (derived from
the height data) of untreated MRSP cells (a, c, e), and MRSP cells
treated with 8 lg/ml fosfomycin (b, d, f). Images were acquired
following the treatment of the MRSP cells for 4 h (a, b), 8 h (c,
d) and 12 h (e, f). Total scanning area for the 8- and 12-h treated
MRSP A12 images are 20 9 20 lm2
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MRSP bacterial surface provides better understanding of
antibacterial mechanism. The nature and degree of outer
membrane damage on the MRSP cells caused by fosfo-
mycin treatment over 4, 8 and 12 h inducing substantial
topographical changes such as the 30 % shrinkage in the
cell size and reduced surface coverage can be observed.
Increased incubation time and the increased fosfomycin
concentration are correlated well with the bacterial outer
membrane damage as observed by the decreased height
from the Fig. 3b, d, f.
On control samples, the MRSP cells are adhered on the
mica surface in well-organized patterns with maximum
contact maintaining structural integrity. In comparison, the
fosfomycin-treated cells appear to lift-off and maintain
physical separation. Clustering effect is observed on con-
trol samples as the cells clump together to form biofilm.
AFM image analysis of fosfomycin-treated MRSP biofilms
shows that the cells are in smaller groups and are attached
individually and sparsely distributed across the mica sub-
strate surface. The total numbers of cells present on the
treated mica sheets were substantially reduced by 80 % and
the remaining cells displayed a tendency to scatter. In
addition, the fosfomycin-treated cells have collapsed and
flattened indicating the characteristic damages such as the
reduced height and the diameter. The structural alterations
characterized by the loss of regular shape are attributed to
the possible cell-wall biosynthesis inhibition mechanism of
fosfomycin. The cell-wall degradation is more pronounced
in 8-h treated cells compared to the 4-h treated MRSP cells.
The occurrence of the defects in the cell wall and the
protoplasts surrounding the cells (Fig. 5a) indicates the
action of fosfomycin on the bacterial peptidoglycan layer.
The cellular proteins have leaked from the cells and appear
as globular structure enclosing the cell clusters. The surface
roughness on the fosfomycin-treated cells indicates the
presence of macro pore distribution (Fig. 5b).
The gram-positive cell is dense with about 20–80 nm
thickness (Dmitriev et al. 2004) and consists of numerous
interconnecting layers of peptidoglycan. The chemical
make-up of this cell wall consists of cables of cross-linked
glycan strands of about 50 nm in width. The cell wall also
consists of teichoic acids and lipoteichoic acids (Silhavy
et al. 2010; Kohanski et al. 2010), while the outer surface
of peptidoglycan is covered with the surface proteins
offering security for the cell’s survival. Hence, the damage
to the cell wall causes loss of inner contents of cell and
thereby leading to cell death. The AFM phase images
between control and fosfomycin-treated cells shows that
the phase difference is large indicating that the cell sur-
faces had different viscoelasticity of the cell surface
regions. This large phase difference also corresponds to the
Fig. 4 Structure of fosfomycin
Fig. 5 a Atomic force micrograph showing the leaking of contents from fosfomycin-treated MRSP A12 cells on the mica surface. b AFM image
showing the surface ultrastructure roughness with mesopores
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height difference showing that the fosfomycin treatment
had exposed the cell surface.
Treatments of 8 lg/mL of fosfomycin on MRSP bio-
films were found to reduce adherence and biofilm structure
on the mica sheet surface. Percent particulate on the mica
surfaces decreased significantly (P \ 0.05) between the
fosfomycin-treated samples and the control MRSP A12
biofilm samples observed through image analysis (Fig. 6).
Comparisons between the samples indicate that surface
area coverage by MRSP biofilm decreased from 85 to 3 %
over 24 h. This large difference in surface coverage indi-
cates the potential of fosfomycin in influencing the adhe-
sion kinetics of MRSP on material surfaces.
It should be emphasized that the AFM imaging of the
MRSP samples on mica sheet surfaces was conducted
under ambient conditions, as it enables high-resolution
imaging. Investigations of the MRSP biofilms and its
adhesion kinetics and antimicrobial mechanism are cur-
rently being undertaken using AFM and nanoscale imaging
tools. In view of a growing resistance of bacteria to many
antibiotics, it is important that a wider range of materials
are examined for their antibacterial potential and the
effects of fosfomycin on MRSP biofilms are of interest to
microbiologists and of pharmaceutical scientists. Further
study is warranted to elucidate the genetic mechanisms
leading to the change in cell morphology to understand
various the multi-drug resistances of MRSP biofilms.
Conclusion
The use of atomic force microscopy allowed to character-
ize the detailed effect of fosfomycin, and thereby helped to
evaluate the range of morphological changes of the
bacterial cell surface. Fosfomycin induces pore like dam-
ages on the envelope of the MRSP cell, and also cell-wall
damage leading to leaking of cell’s contents. It appears that
the fosfomycin has disrupted the peptidoglycan cell-wall
layer and has targeted the membrane components. The
AFM image analysis also reveals that the fosfomycin
inhibits cell division, and prevents the adhesion on the
surface discouraging the biofilm attachment. The micro-
titre plate assay results conform to the atomic force
microscopy image analysis. This is the first visual dem-
onstration of the effect of fosfomycin on MRSP cells. The
effect of fosfomycin on the morphometric and the surface
structure of the MRSP bacterial cells reveal that fosfomy-
cin could be an effective antibiotic agent for treating
infections caused by MRSP biofilms. Further research on
in vivo studies on the efficacy of fosfomycin in treating
MRSP biofilms is recommended.
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